BOTOX + Placebo for BOTOX

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Masseter Muscle Prominence

Conditions

Masseter Muscle Prominence

Trial Timeline

Nov 22, 2023 → Jul 31, 2025

NCT ID

NCT06137287

About BOTOX + Placebo for BOTOX

BOTOX + Placebo for BOTOX is a phase 3 stage product being developed by AbbVie for Masseter Muscle Prominence. The current trial status is completed. This product is registered under clinical trial identifier NCT06137287. Target conditions include Masseter Muscle Prominence.

What happened to similar drugs?

0 of 4 similar drugs in Masseter Muscle Prominence were approved

Approved (0) Terminated (0) Active (4)

🔄Botulinum Toxin Type AAbbViePhase 3

🔄BOTOX + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06137287	Phase 3	Completed	Nov 22, 2023	Jul 31, 2025	Masseter Muscle Prominence
NCT05216250	Phase 2	Completed	Apr 12, 2022	Feb 3, 2025	Upper Limb Essential Tremor (UL ET)
NCT05141006	Phase 2	Completed	Mar 29, 2022	Dec 6, 2024	Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Competing Products

4 competing products in Masseter Muscle Prominence

See all competitors

Product	Company	Stage	Hype Score
Botulinum Toxin Type A	AbbVie	Phase 3	40
BOTOX + Placebo	AbbVie	Phase 3	40
BOTOX + Placebo	AbbVie	Phase 3	40
BOTOX + Placebo	AbbVie	Phase 3	40